Randy A. Hall

Randy A. Hall

Auto-generated profile, based on publicly available information

Randy A. Hall

Department of Pharmacology, Emory University School of Medicine, Atlanta, GA, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2000 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
FKFumihiko Kanai
Fumihiko Kanai
PMPaola A. Marignani
Paola A. Marignani
DSDilara Sarbassova
Dilara Sarbassova
RYRyohei Yagi
Ryohei Yagi
RHRandy A. Hall
Randy A. Hall
MYMichael B. Yaffe
Michael B. Yaffe
The highly conserved and ubiquitously expressed 14‐3‐3 proteins regulate differentiation, cell cycle progression and apoptosis by binding intracellular phosphoproteins involved in signal transduction. By screening in vitro translated cDNA pools for the ability to bind 14‐3‐3, we identified a novel transcriptional co‐activator, TAZ (transcriptional co‐activator with PDZ‐binding motif) as a 14‐3‐3‐binding molecule. TAZ shares homology with Yes‐associated protein (YAP), contains a WW domain and functions as a transcriptional co‐activator by binding to the PPXY motif present on transcription factors. 14‐3‐3 binding requires TAZ phosphorylation on a single serine residue, resulting in the inhibition of TAZ transcriptional co‐activation through 14‐3‐3‐mediated nuclear export. The C‐terminus of TAZ contains a highly conserved PDZ‐binding motif that localizes TAZ into discrete nuclear foci and is essential for TAZ‐stimulated gene transcription. TAZ uses this same motif to bind the PDZ domain‐containing protein NHERF‐2, a molecule that tethers plasma membrane ion channels and receptors to cytoskeletal actin. TAZ may link events at the plasma membrane and cytoskeleton to nuclear transcription in a manner that can be regulated by 14‐3‐3.

1 April 2015 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
JHJörg Hamann
Jörg Hamann
GAGabriela Aust
Gabriela Aust
DADemet Araç
Demet Araç
Felix EngelFelix Engel
Felix Engel
CFCaroline Formstone
Caroline Formstone
HSHelgi B. Schiöth
Helgi B. Schiöth
The Adhesion family forms a large branch of the pharmacologically important superfamily of G protein–coupled receptors (GPCRs). As Adhesion GPCRs increasingly receive attention from a wide spectrum of biomedical fields, the Adhesion GPCR Consortium, together with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classification, proposes a unified nomenclature for Adhesion GPCRs. The new names have ADGR as common dominator followed by a letter and a number to denote each subfamily and subtype, respectively. The new names, with old and alternative names within parentheses, are: ADGRA1 (GPR123), ADGRA2 (GPR124), ADGRA3 (GPR125), ADGRB1 (BAI1), ADGRB2 (BAI2), ADGRB3 (BAI3), ADGRC1 (CELSR1), ADGRC2 (CELSR2), ADGRC3 (CELSR3), ADGRD1 (GPR133), ADGRD2 (GPR144), ADGRE1 (EMR1, F4/80), ADGRE2 (EMR2), ADGRE3 (EMR3), ADGRE4 (EMR4), ADGRE5 (CD97), ADGRF1 (GPR110), ADGRF2 (GPR111), ADGRF3 (GPR113), ADGRF4 (GPR115), ADGRF5 (GPR116, Ig-Hepta), ADGRG1 (GPR56), ADGRG2 (GPR64, HE6), ADGRG3 (GPR97), ADGRG4 (GPR112), ADGRG5 (GPR114), ADGRG6 (GPR126), ADGRG7 (GPR128), ADGRL1 (latrophilin-1, CIRL-1, CL1), ADGRL2 (latrophilin-2, CIRL-2, CL2), ADGRL3 (latrophilin-3, CIRL-3, CL3), ADGRL4 (ELTD1, ETL), and ADGRV1 (VLGR1, GPR98). This review covers all major biologic aspects of Adhesion GPCRs, including evolutionary origins, interaction partners, signaling, expression, physiologic functions, and therapeutic potential.

1 April 1998 in Nature
Verified
Journal Article
Closed access
PDF file
RHRandy A. Hall
Randy A. Hall
RPRichard T Premont
Richard T Premont
CCChung-Wai Chow
Chung-Wai Chow
JBJeremy T. Blitzer
Jeremy T. Blitzer
JPJulie A. Pitcher
Julie A. Pitcher
RLRobert J. Lefkowitz
Robert J. Lefkowitz

1 December 2009 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
PDF file
SRStefanie L. Ritter
Stefanie L. Ritter
RHRandy A. Hall
Randy A. Hall

21 July 1998 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
RHRandy A. Hall
Randy A. Hall
LOLynda S. Ostedgaard
Lynda S. Ostedgaard
RPRichard T Premont
Richard T Premont
JBJeremy T. Blitzer
Jeremy T. Blitzer
NRNadeem Rahman
Nadeem Rahman
RLRobert J. Lefkowitz
Robert J. Lefkowitz
The Na + /H + exchanger regulatory factor (NHERF) binds to the tail of the β 2 -adrenergic receptor and plays a role in adrenergic regulation of Na + /H + exchange. NHERF contains two PDZ domains, the first of which is required for its interaction with the β 2 receptor. Mutagenesis studies of the β 2 receptor tail revealed that the optimal C-terminal motif for binding to the first PDZ domain of NHERF is D-S/T-x-L, a motif distinct from those recognized by other PDZ domains. The first PDZ domain of NHERF-2, a protein that is 52% identical to NHERF and also known as E3KARP, SIP-1, and TKA-1, exhibits binding preferences very similar to those of the first PDZ domain of NHERF. The delineation of the preferred binding motif for the first PDZ domain of the NHERF family of proteins allows for predictions for other proteins that may interact with NHERF or NHERF-2. For example, as would be predicted from the β 2 receptor tail mutagenesis studies, NHERF binds to the tail of the purinergic P2Y1 receptor, a seven-transmembrane receptor with an intracellular C-terminal tail ending in D-T-S-L. NHERF also binds to the tail of the cystic fibrosis transmembrane conductance regulator, which ends in D-T-R-L. Because the preferred binding motif of the first PDZ domain of the NHERF family of proteins is found at the C termini of a variety of intracellular proteins, NHERF and NHERF-2 may be multifunctional adaptor proteins involved in many previously unsuspected aspects of intracellular signaling.

1 September 2005 in Pharmacological Reviews
Verified
Journal Article
Closed access
PDF file
SPSteven C. Prinster
Steven C. Prinster
CHChris Hague
Chris Hague
RHRandy A. Hall
Randy A. Hall
G protein-coupled receptors (GPCRs) are cell surface receptors that mediate physiological responses to a diverse array of stimuli. GPCRs have traditionally been thought to act as monomers, but recent evidence suggests that GPCRs may form dimers (or higher-order oligomers) as part of their normal trafficking and function. In fact, certain GPCRs seem to have a strict requirement for heterodimerization to attain proper surface expression and functional activity. Even those GPCRs that do not absolutely require heterodimerization may still specifically associate with other GPCR subtypes, sometimes resulting in dramatic effects on receptor pharmacology, signaling, and/or internalization. Understanding the specificity and functional significance of GPCR heterodimerization is of tremendous clinical importance since GPCRs are the molecular targets for numerous therapeutic drugs.